Making Gains in HFpEF: An Appraisal of Where We Are Now
In this symposium, we focus on the management of HFpEF and hear from an esteemed faculty on the totality of evidence that places SGLT-2 inhibitors as the only drug class to significantly improve mortality and morbidity in patients with an left ventricular ejection fraction >40%. In addition to hearing about the data which led to changes in the recent ACC guidelines, we’ll also explore the impact of clinical inertia and the remaining challenges in HFpEF management.
This symposium is part of Heart Failure Online 2022, a world-class virtual event dedicated to the latest heart failure treatment strategies to support better patient outcomes.
This programme is intended to educate:
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
Upon participation in this programme physicians should be able to:
- Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
- Recall current inertia rates amongst prescribers who manage heart failure
- Adopt effective treatment strategies for HFpEF patients early in the disease course
- Recall current guideline directed medical therapy options in HFpEF
- Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
This symposium is supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance. The scientific programme has not been influenced in any way by the sponsors. It is not intended for US or UK based healthcare professionals.
Patient Case: Typical Patient with HFpEF - Dr Shelley Zieroth
SGLT-2 Inhibitors in HFpEF: Totality of Evidence in a Nutshell - Dr Javed Butler
Early Initiation of Foundational Therapy in HF: Why The Urgency? - Prof Carolyn Lam
Presenters and Panelists:
Prof Carolyn Lam
Dr Javed Butler
Dr Shelley Zieroth